Osimertinib: A Bright Spot at the End of a Dismal 2020 Osimertinib: A Bright Spot at the End of a Dismal 2020

Approval of the first adjunctive treatment for patients with stage IB to IIIA lung cancer is a harbinger of targeted therapies to come, says Dr Mark Kris.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news